These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32955793)

  • 1. Health care-related time costs in patients with metastatic breast cancer.
    Rocque GB; Williams CP; Ingram SA; Azuero A; Mennemeyer ST; Young Pierce J; Nipp RD; Reeder-Hayes KE; Kenzik KM
    Cancer Med; 2020 Nov; 9(22):8423-8431. PubMed ID: 32955793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
    Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
    Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
    Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
    Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality.
    Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Qin A; Oster G
    BMC Cancer; 2011 Jun; 11():250. PubMed ID: 21676243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
    Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
    Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic burden of metastatic breast cancer: a U.S. managed care perspective.
    Montero AJ; Eapen S; Gorin B; Adler P
    Breast Cancer Res Treat; 2012 Jul; 134(2):815-22. PubMed ID: 22684273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
    Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
    Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
    Modi S; Panageas KS; Duck ET; Bach A; Weinstock N; Dougherty J; Cramer L; Hudis C; Norton L; Seidman A
    J Clin Oncol; 2002 Sep; 20(17):3665-73. PubMed ID: 12202668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
    Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
    J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
    Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
    J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of end-of-life care in metastatic breast cancer.
    Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
    J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective.
    Gupta S; Zhang J; Jerusalem G
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):929-40. PubMed ID: 25130198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
    Weycker D; Edelsberg J; Kartashov A; Barron R; Lyman G
    Chemotherapy; 2012; 58(1):8-18. PubMed ID: 22343254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of illness associated with metastatic breast cancer.
    Rao S; Kubisiak J; Gilden D
    Breast Cancer Res Treat; 2004 Jan; 83(1):25-32. PubMed ID: 14997052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
    Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
    Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a method to determine the cost of breast cancer treatment with chemotherapy at Groote Schuur Hospital, Cape Town, South Africa.
    Guzha NT; Thebe T; Butler N; Valodia PN
    S Afr Med J; 2020 Mar; 110(4):296-301. PubMed ID: 32657741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect costs associated with metastatic breast cancer.
    Wan Y; Gao X; Mehta S; Wang Z; Faria C; Schwartzberg L
    J Med Econ; 2013 Oct; 16(10):1169-78. PubMed ID: 23866016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
    Launois RJ; Reboul-Marty JM; Bonneterre J
    Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.